PF-8600: Phase I data

Top-line data from 9 evaluable patients with advanced solid tumors in the first part of a 2-part, open-label, U.S. and Dutch Phase I trial showed that 0.01-0.3 mg/kg IV PF-8600 every 2 weeks led to 4 ...